Abstract
Markers of endocrine sensitivity
Highlights
Endocrine therapy has been a mainstay of treatment of breast cancer since the late 1800s [1], and it has led to remarkable palliation, mortality reduction and even prevention in women with or at risk for this disease
ER is one of the few tumour markers recommended by the Tumor Marker Guidelines Committee of the American Society of Clinical Oncology for routine use in the evaluation and treatment of patients with breast cancer [7]
Breast Cancer Research Vol 10 Suppl 4 Hayes has partnered with the College of American Pathologists to establish guidelines and proficiency testing for evaluation of another critical marker, human epidermal growth factor receptor (HER)2 [8], and a similar initiative is planned for ER in the future
Summary
Endocrine therapy has been a mainstay of treatment of breast cancer since the late 1800s [1], and it has led to remarkable palliation, mortality reduction and even prevention in women with or at risk for this disease. McGuire and colleagues [3,4,5] showed that prediction of resistance was not absolute, women with ER-negative or low metastatic breast cancers were very unlikely to respond to a variety of anti-oestrogen therapies.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
